Our studies did not use syngeneic tumors, primary human PDX models, or non-ovarian cancer models, but future studies in these models would help elucidate the impact of other immune cells in ATG9A deficient tumors, cancer heterogeneity, and ATG9A’s function in other tumor types. This evidence concerns the gene ATG9A and cancer.